	US 12,458,699 B2
	Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
Vincent Plassat, La Ferté Alais (FR); Benoit Hilbold, Schiltigheim (FR); Aurélia Galus, Weyersheim (FR); Thomas Pointeaux, Reichstett (FR); and Julien Meissonnier, Souffelweyersheim (FR)
Assigned to R.P. Scherer Technologies, LLC, Carson City, NV (US)
Filed by R.P. Scherer Technologies, LLC, Carson City, NV (US)
Filed on Nov. 29, 2021, as Appl. No. 17/536,452.
Application 17/536,452 is a continuation of application No. 16/845,830, filed on Apr. 10, 2020, granted, now 11,185,589.
Claims priority of provisional application 62/832,508, filed on Apr. 11, 2019.
Prior Publication US 2022/0143188 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/14 (2017.01); A61K 31/496 (2006.01); A61K 38/03 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); C07K 16/18 (2006.01)

CPC A61K 47/14 (2013.01) [A61K 31/496 (2013.01); A61K 38/03 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); C07K 16/18 (2013.01)]

14 Claims

1. A pharmaceutical formulation, comprising:

a dispersed powder suspended in the pharmaceutical formulation, the dispersed powder comprising an active pharmaceutical ingredient comprising a synthetic or natural poorly permeable peptide having 5 to 20 amino acids or salt or solvate thereof in an amount of 0.01-5 wt. % of the total weight of the formulation;

a lipophilic phase comprising triglycerides of fatty acids; and

at least one lipophilic surfactant comprising partial esters of polyol and fatty acids,

wherein the pharmaceutical formulation is free of polysaccharides and is a water-free reverse emulsion.